Victoria Werth, MD: Sustained Response With Litifilimab in CLE

Dr. Werth reviews 52-week findings from the phase 2 AMETHYST study of litifilimab in patients with moderate-to-severe cutaneous lupus erythematosus (CLE). She highlights the rapid onset of response observed during the randomized portion of the trial and explains that patients who switched from placebo to litifilimab at Week 24 showed improvement within several weeks and subsequently approached the responses seen in patients treated from the outset. Participants who received litifilimab throughout the study continued to improve across multiple clinical endpoints through Week 52, with maintenance of previously achieved responses. Dr. Werth also notes that treatment was generally well tolerated, with no new safety signals, and that the ongoing phase 3 trial will further evaluate litifilimab’s efficacy and safety in CLE.